https://www.selleckchem.com/pr....oducts/Flavopiridol.
patient-centered care. Future studies should validate PRISM in different clinical settings. The demographics of heart failure are changing. The rate of growth of the "older" heart failure population, specifically those ≥ 75, has outpaced that of any other age group. These older patients were underrepresented in the early beta-blocker trials. There are several reasons, including a decreased potential for mortality benefit and increased risk of side effects, why the risk/benefit tradeoff may be different in this population. We aimed
Like
Comment
Share
